Total Payments
$4,549
2024 Payments
$15.00
Companies
6
Transactions
8
Medicare Patients
1,884
Medicare Billing
$356,488
Payment Breakdown by Category
Research$4,470 (98.3%)
Education$62.59 (1.4%)
Food & Beverage$16.20 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4,470 | 3 | 98.3% |
| Education | $62.59 | 4 | 1.4% |
| Food and Beverage | $16.20 | 1 | 0.4% |
Payments by Type
Research
$4,470
3 transactions
General
$78.79
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $4,470 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $23.65 | 1 | $0 (2023) |
| Biocompatibles, Inc. | $16.20 | 1 | $0 (2019) |
| Aveo Pharmaceuticals, Inc. | $15.00 | 1 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $13.07 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $10.87 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15.00 | 1 | Aveo Pharmaceuticals, Inc. ($15.00) |
| 2023 | $3,224 | 2 | PFIZER INC. ($3,200) |
| 2022 | $1,270 | 2 | PFIZER INC. ($1,270) |
| 2021 | $10.87 | 1 | Merck Sharp & Dohme Corporation ($10.87) |
| 2019 | $16.20 | 1 | Biocompatibles, Inc. ($16.20) |
| 2017 | $13.07 | 1 | Janssen Pharmaceuticals, Inc ($13.07) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 08/04/2023 | E.R. Squibb & Sons, L.L.C. | — | Education | In-kind items and services | $23.65 | General |
| 06/29/2023 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/03/2022 | PFIZER INC. | MEKTOVI (Drug), BRAFTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/10/2022 | PFIZER INC. | MEKTOVI (Drug), BRAFTOVI | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/15/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $10.87 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2019 | Biocompatibles, Inc. | THERASPHERE-BIO (Device) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: INTERVENTIONAL ONCOLOGY | ||||||
| 11/09/2017 | Janssen Pharmaceuticals, Inc | ZYTIGA (Drug) | Education | In-kind items and services | $13.07 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENCORAFENIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 458 | 829 | $250,355 | $63,284 |
| 2022 | 10 | 477 | 931 | $245,355 | $82,329 |
| 2021 | 9 | 499 | 1,123 | $249,450 | $117,287 |
| 2020 | 10 | 450 | 973 | $202,574 | $93,588 |
Total Patients
1,884
Total Services
3,856
Medicare Billing
$356,488
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 153 | 404 | $114,630 | $29,558 | 25.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 66 | 149 | $62,522 | $16,366 | 26.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $22,662 | $5,968 | 26.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 95 | 123 | $23,970 | $5,522 | 23.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 31 | 35 | $7,881 | $1,780 | 22.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $6,821 | $1,404 | 20.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 11 | 13 | $4,267 | $1,007 | 23.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $4,264 | $995.40 | 23.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 22 | 25 | $3,338 | $682.25 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 133 | 363 | $94,223 | $27,200 | 28.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 41 | 124 | $19,840 | $19,805 | 99.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 57 | 122 | $47,294 | $13,963 | 29.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 54 | 54 | $26,434 | $7,590 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 84 | 138 | $24,410 | $6,309 | 25.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 40 | 56 | $13,642 | $2,791 | 20.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $7,216 | $2,055 | 28.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 17 | $5,858 | $1,287 | 22.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $2,656 | $669.67 | 25.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 22 | 25 | $3,782 | $659.27 | 17.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 60 | 324 | $51,840 | $52,367 | 101.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 149 | 404 | $93,389 | $31,249 | 33.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 85 | 146 | $48,332 | $17,275 | 35.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 66 | 91 | $13,781 | $4,509 | 32.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $12,177 | $4,019 | 33.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 28 | 33 | $9,856 | $2,736 | 27.8% |
About Dr. Aimee Kohn, MD
Dr. Aimee Kohn, MD is a Hematology & Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093892648.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aimee Kohn, MD has received a total of $4,549 in payments from pharmaceutical and medical device companies, with $15.00 received in 2024. These payments were reported across 8 transactions from 6 companies. The most common payment nature is "" ($4,470).
As a Medicare-enrolled provider, Kohn has provided services to 1,884 Medicare beneficiaries, totaling 3,856 services with total Medicare billing of $356,488. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Portland, OR
- Active Since 11/01/2006
- Last Updated 07/15/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093892648
Products in Payments
- BRAFTOVI (Drug) $3,200
- MEKTOVI (Drug) $1,270
- THERASPHERE-BIO (Device) $16.20
- FOTIVDA (Drug) $15.00
- ZYTIGA (Drug) $13.07
- KEYTRUDA (Biological) $10.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Portland
Brian Druker, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Dr. Jay Andersen, M.d, M.D
Hematology & Oncology — Payments: $480,702
Hematology & Oncology $480,702
Rachel Sanborn, Md, MD
Hematology & Oncology — Payments: $322,427
Hematology & Oncology $322,427
Richard Maziarz, Md, MD
Hematology & Oncology — Payments: $246,109
Hematology & Oncology $246,109
Tibor Kovacsovics, Md, MD
Hematology & Oncology — Payments: $245,023
Hematology & Oncology $245,023
John Godwin, Md, MD
Hematology & Oncology — Payments: $96,623
Hematology & Oncology $96,623